Viagra drug tested for scleroderma lung complications

NCT ID NCT04797286

Recruiting now Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether sildenafil, a drug used for pulmonary hypertension, can help people with scleroderma who have mildly elevated lung pressures. Thirty participants will receive either sildenafil or a placebo for 4 months. The main goal is to see if the drug improves how far they can walk in 6 minutes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sildenafil (also known as Revatio or Viagra)
What this could lead to: If it works, this could point toward a treatment to improve exercise capacity and heart function in people with scleroderma and mild lung pressure issues.
What could go wrong: This is a small, early-phase trial with only 30 participants. The drug may not improve walking distance or heart function, and side effects like headache or flushing are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MILDLY ELEVATED PULMONARY PRESSURES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse scleroderma pulmonary hypertension scleroderma systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MILDLY ELEVATED PULMONARY PRESSURES SCLERODERMA

Contacts and locations

Locations

Johns Hopkins
RECRUITING

Baltimore, Maryland, 21287, United States
Louisiana State University
NOT_YET_RECRUITING

New Orleans, Louisiana, 70806, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.